A World-First in Genomics, a Saliva Test to Predict Complica

A new agreement has been signed between OPTITHERA, ELNA Medical Group, and Génome Québec as part of Genome Canada's Genomic Applications Partnership Program (GAPP). This partnership will ensure the final steps required to bring to market the first-ever genomic test predicting the risk of diabetic complications.

Related Keywords

Canada , Montreal , Quebec , United States , America , Canadian , Canadians , Johanne Tremblay , Pavel Hamet , Laurent Amram , Group Is Canada , University Of Montreal Hospital Research Centre , Research Centre , University Of Montreal , Genome Canada Genomic Applications Partnership Program , Novel Genomic Derived Score , Diabetes Patients , High Risk , Montreal Hospital Research Centre , Founding President , Genome Canada , Genomic Applications Partnership Program , Elna Medical Group , Innovative Technologies , Precision Medicine , App , énome Québec , Jalna , Healthcare System , Complications , Healthcare Delivery ,